阿维鲁单抗一线维持治疗晚期尿路上皮癌:JAVELIN Bladder 100 3期试验的全面临床亚组分析
JAVELIN Bladder 100 3期试验中,一线铂类化疗后无进展的晚期尿路上皮癌患者随机接受阿维鲁单抗+最佳支持治疗(BSC)或单纯BSC(各350例)。预设及事后亚组分析显示,所有亚组总生存风险比均小于1.0,与总体人群结果一致,支持阿维鲁单抗一线维持为标准治疗。
要点
- 一线铂类化疗后无进展的晚期尿路上皮癌患者,阿维鲁单抗+最佳支持治疗对比单纯最佳支持治疗,所有亚组总生存风险比均小于1.0。
- 顺铂+吉西他滨亚组总生存风险比0.69(95%CI 0.50-0.93),卡铂+吉西他滨亚组0.64(95%CI 0.46-0.90)。
- 部分亚组样本量较小且为事后分析未做多重性校正,无进展生存观察结果与总生存相似。
核心结论
- 临床相关亚组的总生存和无进展生存分析结果与总体人群一致,进一步支持阿维鲁单抗一线维持治疗作为一线铂类化疗后无进展晚期尿路上皮癌患者的标准治疗。
研究设计与样本
- 3期JAVELIN Bladder 100试验(NCT02603432),一线吉西他滨+顺铂或卡铂化疗后无进展的不可切除局部晚期或转移性尿路上皮癌患者,随机接受阿维鲁单抗+最佳支持治疗(n=350)或单纯最佳支持治疗(n=350),两组中位随访均超过19个月(数据截止2019年10月21日)。
- 采用Kaplan-Meier法和Cox比例风险模型分析预设和事后亚组的总生存(主要终点)和无进展生存。
主要发现
- 阿维鲁单抗+最佳支持治疗对比单纯最佳支持治疗的总生存风险比在所有 examined 亚组中均小于1.0。
- 一线顺铂+吉西他滨治疗患者总生存风险比0.69(95%CI 0.50-0.93),一线卡铂+吉西他滨治疗患者0.64(95%CI 0.46-0.90)。
- PD-L1阳性肿瘤且接受卡铂+吉西他滨治疗患者总生存风险比0.67(95%CI 0.39-1.14)。
- 化疗最佳疗效为完全缓解者总生存风险比0.80(95%CI 0.46-1.37),部分缓解者0.62(95%CI 0.46-0.84),疾病稳定者0.70(95%CI 0.46-1.06)。
- 无进展生存的观察结果与总生存相似。
关键数值与推荐
- 阿维鲁单抗+最佳支持治疗对比单纯最佳支持治疗的总生存风险比在所有 examined 亚组中均小于1.0。
临床怎么用
- 原文结论支持阿维鲁单抗一线维持治疗作为一线铂类化疗后无进展晚期尿路上皮癌患者的标准治疗。
局限性
- 部分亚组样本量较小。
- 部分亚组为事后分析且未做多重性校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance + best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (aUC) who were progression-free following 1L platinum-based chemotherapy, leading to regulatory approval in various countries. OBJECTIVE: To analyze clinically relevant subgroups from JAVELIN Bladder 100. DESIGN, SETTING, AND PARTICIPANTS: Patients with unresectable locally advanced or metastatic UC without progression on 1L gemcitabine + cisplatin or carboplatin were randomized to receive avelumab + BSC (n = 350) or BSC alone (n = 350). Median follow-up was >19 mo in both arms (data cutoff October 21, 2019). This trial is registered on ClinicalTrials.gov as NCT02603432. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: OS (primary endpoint) and PFS were analyzed in protocol-specified and post hoc subgroups using the Kaplan-Meier method and Cox proportional hazards models. RESULTS AND LIMITATIONS: Hazard ratios (HRs) for OS with avelumab + BSC versus BSC alone were <1.0 across all subgroups examined, including patients treated with 1L cisplatin + gemcitabine (HR 0.69, 95% confidence interval [CI] 0.50-0.93) or carboplatin + gemcitabine (HR 0.64, 95% CI 0.46-0.90), patients with PD-L1+ tumors treated with carboplatin + gemcitabine (HR 0.67, 95% CI 0.39-1.14), and patients whose best response to chemotherapy was a complete response (HR 0.80, 95% CI 0.46-1.37), partial response (HR 0.62, 95% CI 0.46-0.84), or stable disease (HR 0.70, 95% CI 0.46-1.06). Observations were similar for PFS. Limitations include the smaller size and post hoc evaluation without multiplicity adjustment for some subgroups. CONCLUSIONS: Analyses of OS and PFS in clinically relevant subgroups were consistent with results for the overall population, further supporting avelumab 1L maintenance as standard-of-care treatment for patients with aUC who are progression-free following 1L platinum-based chemotherapy. PATIENT SUMMARY: In the JAVELIN Bladder 100 study, maintenance treatment with avelumab helped many different groups of people with advanced cancer of the urinary tract to live longer.
引用
- Grivas P, Park SH, Voog E, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol. 2023. PMID: 37121850. doi:10.1016/j.eururo.2023.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。